1201080-09-2Relevant articles and documents
New synthesis of N-(4-chloro-3-cyano-7-ethoxyquinolin- 6-yl)acetamide
Mao, Yongjun,He, Yang,Zhu, Fuqiang,Chen, Weiming,Shen, Jingshan,Li, Jianfeng
, p. 1203 - 1209 (2014)
New synthetic route of N-(4-chloro-3-cyano-7-ethoxyquinolin-6-yl)- acetamide (1) is described on a hectogram scale. The key steps include the intramolecular cyclization of 3-amino-2-(2-chlorobenzoyl)acrylonitrile 22 to give the 3-cyano-4-quinolone 7, which was chlorinated by POCl3 to give the final product 1 in 36.9% yield over 9 steps and 98.9% purity (HPLC). Purification methods of 7 and 1 were also given.
New and practical synthesis of N-(3-Cyano-7-ethoxy-4-oxo-1,4- dihydroquinolin-6-yl)acetamide
Ma, Wenpeng,Mao, Yongjun,Xie, Kai,Zhu, Qifeng,Zhang, Rongxia,Shen, Jingshan,Sun, Hongbin
, p. 866 - 868 (2014/06/10)
New and practical synthetic route of N-(3-cyano-7-ethoxy-4-oxo-1,4- dihydroquinolin-6-yl)acetamide (1) is described, through the cyclization of 2-aminophenyl-ethanone (12) with N,N-dimethylformamide dimethylacetal. The overall yield of 1 obtained from this process is 46% (five steps) with a purity of >99% (HPLC).
Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides
Carmi, Caterina,Galvani, Elena,Vacondio, Federica,Rivara, Silvia,Lodola, Alessio,Russo, Simonetta,Aiello, Stefania,Bordi, Fabrizio,Costantino, Gabriele,Cavazzoni, Andrea,Alfieri, Roberta R.,Ardizzoni, Andrea,Petronini, Pier Giorgio,Mor, Marco
scheme or table, p. 2251 - 2264 (2012/05/20)
Irreversible epidermal growth factor receptor (EGFR) inhibitors contain a reactive warhead which covalently interacts with a conserved cysteine residue in the kinase domain. The acrylamide fragment, a commonly employed warhead, effectively alkylates Cys797 of EGFR, but its reactivity can cause rapid metabolic deactivation or nonspecific reactions with off-targets. We describe here a new series of irreversible inhibitors containing a 3-aminopropanamide linked in position 6 to 4-anilinoquinazoline or 4-anilinoquinoline-3- carbonitrile driving portions. Some of these compounds proved to be as efficient as their acrylamide analogues in inhibiting EGFR-TK (TK = tyrosine kinase) autophosphorylation in A549 lung cancer cells. Moreover, several 3-aminopropanamides suppressed proliferation of gefitinib-resistant H1975 cells, harboring the T790M mutation in EGFR, at significantly lower concentrations than did gefitinib. A prototypical compound, N-(4-(3-bromoanilino)quinazolin-6- yl)-3-(dimethylamino)propanamide (5), did not show covalent binding to cell-free EGFR-TK in a fluorescence assay, while it underwent selective activation in the intracellular environment, releasing an acrylamide derivative which can react with thiol groups.